607702-99-8
Chemical Structure
BCR-ABL-IN-13
- CAS No.: 607702-99-8
- Formula:C16H11F2N3OS2
- Molecular Weight:363.40
IUPAC Name: 4-fluoro-N-(5-((4-fluorobenzyl)thio)-1,3,4-thiadiazol-2-yl)benzamide
InChIKey: ZDYQINDXPNAOKX-UHFFFAOYSA-N
SMILES: O=C(NC1=NN=C(S1)SCC2=CC=C(F)C=C2)C3=CC=C(F)C=C3
Biological Activity: BCR-ABL-IN-13 is a dual c-Src and Abl inhibitor, with a Ki value of 0.55 μM against c-Src, 0.10 μM against wild-type Abl, and 0.40 μM against the AblT315I mutant. BCR-ABL-IN-13 exerts competitive/mixed-type inhibitory effects on wild-type Abl, and non-competitive inhibitory effects on the drug-resistant AblT315I mutant. BCR-ABL-IN-13 can be used for the research of chronic myeloid leukemia[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BCR-ABL-IN-13 | 99.86% | BCR-ABL-IN-13 is a dual c-Src and Abl inhibitor, with a Ki value of 0.55 μM against c-Src, 0.10 μM against wild-type Abl, and 0.40 μM against the AblT315I mutant. BCR-ABL-IN-13 exerts competitive/mixed-type inhibitory effects on wild-type Abl, and non-competitive inhibitory effects on the drug-resistant AblT315I mutant. BCR-ABL-IN-13 can be used for the research of chronic myeloid leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
